From botanical raw material validation to pilot batch generation and clinical substantiation, access our specialized research modules engineered to drive commercial product differentiation.
In an era of intense market transparency, regulatory scrutiny, and consumer skepticism, the nutraceutical landscape is moving away from arbitrary "kitchen-sink" formulation. Today’s global wellness enterprises face unprecedented friction: rising customer acquisition costs, stringently monitored structure/function claim regulations by the US FDA and EFSA, and an increasingly discerning end-user demanding quantifiable biological outcomes. As a Tier-1 ODM innovative dietary supplements manufacturer & supplier, MedGence (Yineng Pharma) operates at the convergence of pharmaceutical contract research (CRO) and precision contract development and manufacturing (CDMO).
Headquartered in the biomedical innovation hub of Changsha, China, MedGence leverages more than 14 years of rigorous translational medicine. Our scientific infrastructure integrates over 300 multidisciplinary research scientists, toxicologists, and process engineers. Rather than functioning as a standard packaging assembler, our enterprise de-risks commercial supplement innovation by bridging classical botanical intelligence—such as 83 modernized classic Traditional Chinese Medicine (TCM) pharmacopeia formulations—with modern chromatography, cellular targeted assays, and GCP-compliant clinical validation.
By operating our proprietary pilot testing plants alongside state-of-the-art cGMP production facilities, MedGence eliminates the costly "valley of death" commonly occurring when moving formulations from small-scale academic bench discovery to high-speed commercial production lines. Our mission delivers absolute chemical stability, maximized bioavailability, and ironclad regulatory compliance.
Translating complex pharmacological hurdles into commercial turnkey solutions with optimized pharmacokinetics, physical stability, and transparent regulatory filing.
Many valuable phytochemicals—such as curcuminoids, berberine, and quercetin—exhibit inherently low water solubility and rapid hepatic first-pass metabolism. MedGence formulates with proprietary micro-emulsification, phytosomal complexation, and lipid nanoparticle encapsulation to multiply gastrointestinal absorption rates exponentially.
Crude agricultural botanicals suffer extreme potency volatility caused by geographic origin, harvest seasonality, and post-harvest drying techniques. We implement HPLC-MS, HPTLC, and GC-FID fingerprinting to ensure that every finished dose contains the exact designated concentration of bioactive markers.
Consumer adoption frequently fails due to hygroscopic herbal degradation, oxidation, unpleasant bitterness, or astringency. Our food technologists develop specialized natural masking matrices and taste-masking spray coatings without compromising the active molecule release profiles.
Leveraging automated closed-loop extraction, MES real-time traceability, and direct domestic agricultural cultivation networks to deliver maximum cost-efficiency.
By establishing GAP-compliant (Good Agricultural Practices) herb cultivation bases across China's major agro-climatic zones (e.g., Hunan, Yunnan, Sichuan, and Changbai Mountain), MedGence secures supply chain immunity against global raw-material commodity fluctuations. We manage first-hand botanical sourcing, ensuring unadulterated raw origins from harvest to extraction.
Our collaborative industrial base features automated supercritical CO2 fluid extraction, multi-stage countercurrent extraction towers, and continuous ceramic membrane filtration modules. Controlled by supervisory SCADA and Manufacturing Execution Systems (MES), every thermal run, solvent recovery cycle, and vacuum drying parameter is logged to provide immutable batch accountability.
Western contract manufacturers often require 12 to 18 months for pilot formulations and scale-up due to disjointed testing subcontractors. MedGence's integrated CRO-CDMO architecture consolidates active ingredient screening, analytical assay design, stability testing, and commercial filling into an agile 12-to-16-week launch runway, allowing partners to capture emergent wellness trends quickly.
From bulk concentrated raw active compounds to consumer-ready finished packaged stock keeping units (SKUs).
Supplied directly to overseas manufacturing facilities requiring highly standardized phytocompounds with ultra-low residual solvents and micro-contaminants:
End-to-end turnkey OEM/ODM encapsulation, compression, blister packaging, bottling, and cleanroom sachet packing adhering to global standards:
Anticipating shifting search queries and clinical demands: Synbiotics, Cellular Longevity, AI Screening, and Epigenetic Nutrients.
MedGence is actively deploying in silico computational biology algorithms and machine learning models to map polypharmacological plant molecules against specific biological targets (such as AMPK activation, sirtuins, and GLP-1 receptor modulation), drastically reducing upfront CRO screening schedules.
The global anti-aging supplement market is shifting toward senolytic botanicals and NAD+ replenishment precursors. Our R&D pipelines encompass next-generation pterostilbene, fisetin, and specialized cyclic peptide extracts demonstrating high stability and bioavailability.
Beyond traditional live probiotic cultures prone to ambient degradation, MedGence manufactures heat-stable postbiotic metabolites, polyphenolic microbiome fermentation substrates, and protective prebiotics engineered to withstand stomach acid and thermal transport stress.
Overcoming border friction through rigorous testing, verified Chain-of-Custody records, and complete regulatory submission packages.
Full adherence to Current Good Manufacturing Practices for Dietary Supplements. Every production run is supported by Batch Production Records (BPR), verified identity testing of 100% incoming lots, residual solvent testing (USP <467>), and heavy metal screening (USP <2232>).
Meeting California Proposition 65 limits requires extreme analytical precision. MedGence employs inductively coupled plasma mass spectrometry (ICP-MS) and GC-MS/MS testing for ethylene oxide (EtO), polycyclic aromatic hydrocarbons (PAHs), and multi-residue pesticide screens covering over 500 compounds.
For novel phytochemical ingredients seeking New Dietary Ingredient (NDI) or Generally Recognized As Safe (GRAS) status in North America, or Novel Food authorization in the EU, MedGence provides complete toxicological dossiers: in vitro Ames tests, in vivo micronucleus assays, 90-day subchronic toxicity studies, and Phase I–IV clinical outcome evaluations.
Our contract research and precision manufacturing backbone supports premier medical universities, clinical research hospitals, and global pharmaceutical groups.
Beijing Tongrentang Group
CR Sanjiu Pharmaceutical
Sunflower Pharmaceutical Group
Livzon Pharmaceutical Group
Dihon Pharmaceutical
Golden Throat Holdings
Yangtzi River Pharma
Humanwell Healthcare
Luoxin Pharmaceutical
Zhongsheng Pharma
Apeloa Pharmaceutical
Shuguang Hospital (Shanghai TCM)
Hunan Affiliated TCM Hospital
2nd Xiangya Hospital (CSU)
Clear, direct operational insight for Chief Scientific Officers, R&D Vice Presidents, and Global Strategic Procurement Directors.
Select your target research module to initiate custom laboratory design, clinical evaluation, or commercial CDMO production.
Accelerate your product development cycle with validated phytochemical screening, precise chromatographic quality controls, and certified cGMP manufacturing. Contact our Changsha research center at [email protected].
